Takeda Healthcare Philippines Inc. (“Takeda Philippines”) joined the World
Health Organization (WHO) for World Immunization Week 2023 heeding the latter's
call for protecting millions of people around the world from
vaccine-preventable diseases.
Takeda Philippines is proud to support WHO’s
World Immunization Week for the second year in a row, with this year’s theme,
#TheBigCatchUp. Working with partners and volunteers all around the world, WHO
wants to ensure that people, especially children, are on track with their
vaccinations, to restore essential immunization coverage to 2019 levels, and to
strengthen vaccine deliveries through primary healthcare. World Immunization
Week is a yearly campaign by the WHO aiming to bring awareness and reflect on
the essential role vaccinations play in promoting global health.
“Immunizations are an essential asset for global
public health and a basic health care right to help protect families and
communities against infectious disease,” Shun Mori, Head of the Established
Vaccine Program and Japan Business Coordinator, spoke about the importance of WHO’s World Immunization Week campaign.
“Takeda has supplied vaccines against burdensome
diseases for the individuals of Japan, and we take pride in furthering this
effort to continue bettering the health of people all around the world.” he
added.
Unwavering Commitment to Vaccine Innovation & Vaccine for All
Takeda has dedicated more than 70 years in
developing and providing vaccines in Japan, facing the most difficult problems
in public health by developing innovative vaccines to prevent the spread of new
diseases. Today, they have taken the challenge of introducing a new vaccine for
one of the most challenging infectious diseases known to mankind, Dengue.
Takeda has recently developed a dengue vaccine
aimed to curb the deadly dengue disease regardless of previous exposure. Dengue
is a mosquito-borne viral disease common in many tropical countries such as the
Philippines, and is listed by the WHO as one of the ten threats to global
health. The vaccine is currently approved for use in Brazil, Indonesia and
Thailand where dengue is endemic[1]. The
vaccine is also approved for use in the European Union.
Takeda has developed a
new vaccine for the deadly Dengue virus, which has now been approved for use in
Brazil, Indonesia, Thailand and the European Union.
“We look forward to bringing Takeda’s dengue
vaccine to the Philippines in the near future. We will work with the government
and private sectors to address the burden of the dengue disease which has long
remained endemic for decades and is responsible for over 200,000 cases in 2022
alone,” shared Loreann Villanueva, Country Manager of Takeda Healthcare Philippines.
Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical
company.
# # #
About
Takeda
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based,
R&D-driven biopharmaceutical leader headquartered in Japan, committed to
discover and deliver life-transforming treatments, guided by our commitment to
patients, our people and the planet. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and
Gastroenterology (GI). We also make targeted R&D investments in
Plasma-Derived Therapies and Vaccines. We are focusing on developing highly
innovative medicines that contribute to making a difference in people’s lives
by advancing the frontier of new treatment options and leveraging our enhanced
collaborative R&D engine and capabilities to create a robust, modality-diverse
pipeline. Our employees are committed to improving quality of life for patients
and to working with our partners in health care in approximately 80 countries
and regions.
Takeda
Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda
Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient
access to treatment across the country through sustainable access programs
enabling affordable and integrated access solutions for disease areas such as
oncology, gastroenterology, rare diseases & vaccines and by strengthening
the healthcare system guided by our commitment to Patients, our People and the
Planet.
For more information, visit https://www.takeda.com.
Important Notice
For
the purposes of this notice, “press release” means this document, any oral
presentation, any question and answer session and any written or oral material
discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral briefing and any
question-and-answer in connection with it) is not intended to, and does not
constitute, represent or form part of any offer, invitation or solicitation of
any offer to purchase, otherwise acquire, subscribe for, exchange, sell or
otherwise dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are being offered
to the public by means of this press release. No offering of securities shall
be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This press
release is being given (together with any further information which may be
provided to the recipient) on the condition that it is for use by the recipient
for information purposes only (and not for the evaluation of any investment,
acquisition, disposal or any other transaction). Any failure to comply with
these restrictions may constitute a violation of applicable securities laws.
The
companies in which Takeda directly and indirectly owns investments are separate
entities. In this press release, “Takeda” is sometimes used for convenience
where references are made to Takeda and its subsidiaries in general. Likewise,
the words “we”, “us” and “our” are also used to refer to subsidiaries in
general or to those who work for them. These expressions are also used where no
useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This
press release and any materials distributed in connection with this press
release may contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of operations, including
estimates, forecasts, targets and plans for Takeda. Without limitation,
forward-looking statements often include words such as “targets”, “plans”,
“believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”,
“would”, “could” “anticipates”, “estimates”, “projects” or similar expressions
or the negative thereof. These forward-looking statements are based on
assumptions about many important factors, including the following, which could
cause actual results to differ materially from those expressed or implied by
the forward-looking statements: the economic circumstances surrounding Takeda’s
global business, including general economic conditions in Japan and the United States;
competitive pressures and developments; changes to applicable laws and
regulations, including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and decisions of
regulatory authorities and the timing thereof; uncertainty of commercial
success for new and existing products; manufacturing difficulties or delays;
fluctuations in interest and currency exchange rates; claims or concerns
regarding the safety or efficacy of marketed products or product candidates;
the impact of health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in countries in
which Takeda operates, or on other facets of its business; the timing and impact
of post-merger integration efforts with acquired companies; the ability to
divest assets that are not core to Takeda’s operations and the timing of any
such divestment(s); and other factors identified in Takeda’s most recent Annual
Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities
and Exchange Commission, available on Takeda’s website at:
https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does
not undertake to update any of the forward-looking statements contained in this
press release or any other forward-looking statements it may make, except as
required by law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this press release
may not be indicative of, and are not an estimate, forecast, guarantee or
projection of Takeda’s future results.
Medical information
This
press release contains information about products that may not be available in
all countries, or may be available under different trademarks, for different
indications, in different dosages, or in different strengths. Nothing contained
herein should be considered a solicitation, promotion or advertisement for any
prescription drugs including the ones under development.
Takeda Healthcare Philippines Inc. (“Takeda Philippines”) joined the World
Health Organization (WHO) for World Immunization Week 2023 heeding the latter's
call for protecting millions of people around the world from
vaccine-preventable diseases.
Takeda Philippines is proud to support WHO’s
World Immunization Week for the second year in a row, with this year’s theme,
#TheBigCatchUp. Working with partners and volunteers all around the world, WHO
wants to ensure that people, especially children, are on track with their
vaccinations, to restore essential immunization coverage to 2019 levels, and to
strengthen vaccine deliveries through primary healthcare. World Immunization
Week is a yearly campaign by the WHO aiming to bring awareness and reflect on
the essential role vaccinations play in promoting global health.
“Immunizations are an essential asset for global
public health and a basic health care right to help protect families and
communities against infectious disease,” Shun Mori, Head of the Established
Vaccine Program and Japan Business Coordinator, spoke about the importance of WHO’s World Immunization Week campaign.
“Takeda has supplied vaccines against burdensome
diseases for the individuals of Japan, and we take pride in furthering this
effort to continue bettering the health of people all around the world.” he
added.
Unwavering Commitment to Vaccine Innovation & Vaccine for All
Takeda has dedicated more than 70 years in
developing and providing vaccines in Japan, facing the most difficult problems
in public health by developing innovative vaccines to prevent the spread of new
diseases. Today, they have taken the challenge of introducing a new vaccine for
one of the most challenging infectious diseases known to mankind, Dengue.
Takeda has recently developed a dengue vaccine
aimed to curb the deadly dengue disease regardless of previous exposure. Dengue
is a mosquito-borne viral disease common in many tropical countries such as the
Philippines, and is listed by the WHO as one of the ten threats to global
health. The vaccine is currently approved for use in Brazil, Indonesia and
Thailand where dengue is endemic[1]. The
vaccine is also approved for use in the European Union.
TTakeda Healthcare Philippines Inc. (“Takeda Philippines”) joined the World
Health Organization (WHO) for World Immunization Week 2023 heeding the latter's
call for protecting millions of people around the world from
vaccine-preventable diseases.
Takeda Philippines is proud to support WHO’s
World Immunization Week for the second year in a row, with this year’s theme,
#TheBigCatchUp. Working with partners and volunteers all around the world, WHO
wants to ensure that people, especially children, are on track with their
vaccinations, to restore essential immunization coverage to 2019 levels, and to
strengthen vaccine deliveries through primary healthcare. World Immunization
Week is a yearly campaign by the WHO aiming to bring awareness and reflect on
the essential role vaccinations play in promoting global health.
“Immunizations are an essential asset for global
public health and a basic health care right to help protect families and
communities against infectious disease,” Shun Mori, Head of the Established
Vaccine Program and Japan Business Coordinator, spoke about the importance of WHO’s World Immunization Week campaign.
“Takeda has supplied vaccines against burdensome
diseases for the individuals of Japan, and we take pride in furthering this
effort to continue bettering the health of people all around the world.” he
added.
Unwavering Commitment to Vaccine Innovation & Vaccine for All
Takeda has dedicated more than 70 years in
developing and providing vaccines in Japan, facing the most difficult problems
in public health by developing innovative vaccines to prevent the spread of new
diseases. Today, they have taken the challenge of introducing a new vaccine for
one of the most challenging infectious diseases known to mankind, Dengue.
Takeda has recently developed a dengue vaccine
aimed to curb the deadly dengue disease regardless of previous exposure. Dengue
is a mosquito-borne viral disease common in many tropical countries such as the
Philippines, and is listed by the WHO as one of the ten threats to global
health. The vaccine is currently approved for use in Brazil, Indonesia and
Thailand where dengue is endemic[1]. The
vaccine is also approved for use in the European Union.
Takeda has developed a
new vaccine for the deadly Dengue virus, which has now been approved for use in
Brazil, Indonesia, Thailand and the European Union.
“We look forward to bringing Takeda’s dengue
vaccine to the Philippines in the near future. We will work with the government
and private sectors to address the burden of the dengue disease which has long
remained endemic for decades and is responsible for over 200,000 cases in 2022
alone,” shared Loreann Villanueva, Country Manager of Takeda Healthcare Philippines.
Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical
company.
# # #
About
Takeda
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based,
R&D-driven biopharmaceutical leader headquartered in Japan, committed to
discover and deliver life-transforming treatments, guided by our commitment to
patients, our people and the planet. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and
Gastroenterology (GI). We also make targeted R&D investments in
Plasma-Derived Therapies and Vaccines. We are focusing on developing highly
innovative medicines that contribute to making a difference in people’s lives
by advancing the frontier of new treatment options and leveraging our enhanced
collaborative R&D engine and capabilities to create a robust, modality-diverse
pipeline. Our employees are committed to improving quality of life for patients
and to working with our partners in health care in approximately 80 countries
and regions.
Takeda
Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda
Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient
access to treatment across the country through sustainable access programs
enabling affordable and integrated access solutions for disease areas such as
oncology, gastroenterology, rare diseases & vaccines and by strengthening
the healthcare system guided by our commitment to Patients, our People and the
Planet.
For more information, visit https://www.takeda.com.
Media Contacts:
Takeda Philippines
Arabella
Benito - arabella.benito@takeda.com
COMCO
Southeast Asia
Ferdinand Bondoy -
ferdinand.bondoy@comcosea.com
Joyce Yu - joyce.yu@comcosea.com
Pinky Tuason – pinky.tuason@comcosea.com
Important Notice
For
the purposes of this notice, “press release” means this document, any oral
presentation, any question and answer session and any written or oral material
discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral briefing and any
question-and-answer in connection with it) is not intended to, and does not
constitute, represent or form part of any offer, invitation or solicitation of
any offer to purchase, otherwise acquire, subscribe for, exchange, sell or
otherwise dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are being offered
to the public by means of this press release. No offering of securities shall
be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This press
release is being given (together with any further information which may be
provided to the recipient) on the condition that it is for use by the recipient
for information purposes only (and not for the evaluation of any investment,
acquisition, disposal or any other transaction). Any failure to comply with
these restrictions may constitute a violation of applicable securities laws.
The
companies in which Takeda directly and indirectly owns investments are separate
entities. In this press release, “Takeda” is sometimes used for convenience
where references are made to Takeda and its subsidiaries in general. Likewise,
the words “we”, “us” and “our” are also used to refer to subsidiaries in
general or to those who work for them. These expressions are also used where no
useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This
press release and any materials distributed in connection with this press
release may contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of operations, including
estimates, forecasts, targets and plans for Takeda. Without limitation,
forward-looking statements often include words such as “targets”, “plans”,
“believes”,
“hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”,
“would”, “could” “anticipates”, “estimates”, “projects” or similar expressions
or the negative thereof. These forward-looking statements are based on
assumptions about many important factors, including the following, which could
cause actual results to differ materially from those expressed or implied by
the forward-looking statements: the economic circumstances surrounding Takeda’s
global business, including general economic conditions in Japan and the United States;
competitive pressures and developments; changes to applicable laws and
regulations, including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and decisions of
regulatory authorities and the timing thereof; uncertainty of commercial
success for new and existing products; manufacturing difficulties or delays;
fluctuations in interest and currency exchange rates; claims or concerns
regarding the safety or efficacy of marketed products or product candidates;
the impact of health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in countries in
which Takeda operates, or on other facets of its business; the timing and impact
of post-merger integration efforts with acquired companies; the ability to
divest assets that are not core to Takeda’s operations and the timing of any
such divestment(s); and other factors identified in Takeda’s most recent Annual
Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities
and Exchange Commission, available on Takeda’s website at:
https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does
not undertake to update any of the forward-looking statements contained in this
press release or any other forward-looking statements it may make, except as
required by law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this press release
may not be indicative of, and are not an estimate, forecast, guarantee or
projection of Takeda’s future results.
Medical information
This
press release contains information about products that may not be available in
all countries, or may be available under different trademarks, for different
indications, in different dosages, or in different strengths. Nothing contained
herein should be considered a solicitation, promotion or advertisement for any
prescription drugs including the ones under development.
“We look forward to bringing Takeda’s dengue
vaccine to the Philippines in the near future. We will work with the government
and private sectors to address the burden of the dengue disease which has long
remained endemic for decades and is responsible for over 200,000 cases in 2022
alone,” shared Loreann Villanueva, Country Manager of Takeda Healthcare Philippines.
Takeda Healthcare Philippines is a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical
company.
About
Takeda
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based,
R&D-driven biopharmaceutical leader headquartered in Japan, committed to
discover and deliver life-transforming treatments, guided by our commitment to
patients, our people and the planet. Takeda focuses its R&D efforts on four
therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and
Gastroenterology (GI). We also make targeted R&D investments in
Plasma-Derived Therapies and Vaccines. We are focusing on developing highly
innovative medicines that contribute to making a difference in people’s lives
by advancing the frontier of new treatment options and leveraging our enhanced
collaborative R&D engine and capabilities to create a robust, modality-diverse
pipeline. Our employees are committed to improving quality of life for patients
and to working with our partners in health care in approximately 80 countries
and regions.
Takeda
Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda
Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient
access to treatment across the country through sustainable access programs
enabling affordable and integrated access solutions for disease areas such as
oncology, gastroenterology, rare diseases & vaccines and by strengthening
the healthcare system guided by our commitment to Patients, our People and the
Planet.
For more information, visit https://www.takeda.com.
Media Contacts:
Takeda Philippines
Arabella
Benito - arabella.benito@takeda.com
COMCO
Southeast Asia
Ferdinand Bondoy -
ferdinand.bondoy@comcosea.com
Joyce Yu - joyce.yu@comcosea.com
Pinky Tuason – pinky.tuason@comcosea.com
Important Notice
For
the purposes of this notice, “press release” means this document, any oral
presentation, any question and answer session and any written or oral material
discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral briefing and any
question-and-answer in connection with it) is not intended to, and does not
constitute, represent or form part of any offer, invitation or solicitation of
any offer to purchase, otherwise acquire, subscribe for, exchange, sell or
otherwise dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are being offered
to the public by means of this press release. No offering of securities shall
be made in the United States except pursuant to registration under the U.S.
Securities Act of 1933, as amended, or an exemption therefrom. This press
release is being given (together with any further information which may be
provided to the recipient) on the condition that it is for use by the recipient
for information purposes only (and not for the evaluation of any investment,
acquisition, disposal or any other transaction). Any failure to comply with
these restrictions may constitute a violation of applicable securities laws.
The
companies in which Takeda directly and indirectly owns investments are separate
entities. In this press release, “Takeda” is sometimes used for convenience
where references are made to Takeda and its subsidiaries in general. Likewise,
the words “we”, “us” and “our” are also used to refer to subsidiaries in
general or to those who work for them. These expressions are also used where no
useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This
press release and any materials distributed in connection with this press
release may contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of operations, including
estimates, forecasts, targets and plans for Takeda. Without limitation,
forward-looking statements often include words such as “targets”, “plans”,
“believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”,
“would”, “could” “anticipates”, “estimates”, “projects” or similar expressions
or the negative thereof. These forward-looking statements are based on
assumptions about many important factors, including the following, which could
cause actual results to differ materially from those expressed or implied by
the forward-looking statements: the economic circumstances surrounding Takeda’s
global business, including general economic conditions in Japan and the United States;
competitive pressures and developments; changes to applicable laws and
regulations, including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and decisions of
regulatory authorities and the timing thereof; uncertainty of commercial
success for new and existing products; manufacturing difficulties or delays;
fluctuations in interest and currency exchange rates; claims or concerns
regarding the safety or efficacy of marketed products or product candidates;
the impact of health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in countries in
which Takeda operates, or on other facets of its business; the timing and impact
of post-merger integration efforts with acquired companies; the ability to
divest assets that are not core to Takeda’s operations and the timing of any
such divestment(s); and other factors identified in Takeda’s most recent Annual
Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities
and Exchange Commission, available on Takeda’s website at:
https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does
not undertake to update any of the forward-looking statements contained in this
press release or any other forward-looking statements it may make, except as
required by law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this press release
may not be indicative of, and are not an estimate, forecast, guarantee or
projection of Takeda’s future results.
Medical information
This
press release contains information about products that may not be available in
all countries, or may be available under different trademarks, for different
indications, in different dosages, or in different strengths. Nothing contained
herein should be considered a solicitation, promotion or advertisement for any
prescription drugs including the ones under development.
